| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,006 | 0,007 | 15.05. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.04. | Aptamer Group PLC - Result of General Meeting | 1 | RNS | ||
| 31.03. | Aptamer Group PLC - Result of Retail Offer and Posting of Notice of GM | 1 | RNS | ||
| 26.03. | TRADING UPDATES: LPA to meet consensus; Aptamer raises GBP4.28 million | 3 | Alliance News | ||
| APTAMER GROUP Aktie jetzt für 0€ handeln | |||||
| 26.03. | Aptamer Group PLC - Retail Offer to raise up to £0.5 million | 2 | RNS | ||
| 26.03. | Aptamer Group PLC - Results of Placing | - | RNS | ||
| 25.03. | Aptamer reports "meaningful" first-half progress alongside fundraise | 3 | Alliance News | ||
| 25.03. | Aptamer Group: Partnership cash helping to fund development | 1 | The Armchair Trader | ||
| 25.03. | Pharma-Verträge treiben Umsatz der Aptamer Group um 27 % | 1 | Investing.com Deutsch | ||
| 25.03. | Aptamer Group reports 27% revenue increase in first half | 2 | Investing.com | ||
| 25.03. | Aptamer Group PLC - Interim Results and Notice of Investor Webinar | 3 | RNS | ||
| 25.03. | Aptamer Group PLC - Proposed Placing, Subscription and Retail Offer | 1 | RNS | ||
| 18.03. | Aptamer Group Introduces Targeted Radiopharmaceutical Program | 1 | Contract Pharma | ||
| 18.03. | Aptamer launches targets radiopharma development programme | 2 | Sharecast | ||
| 18.03. | Aptamer Group PLC - Launch of targeted radiopharmaceutical programme | - | RNS | ||
| 17.02. | Aptamer Group meldet wichtigen Meilenstein bei Projekt zur Pathogenerkennung | 2 | Investing.com Deutsch | ||
| 17.02. | Aptamer Group achieves technical milestone in pathogen detection project | 1 | Investing.com | ||
| 17.02. | Aptamer Group PLC - Technical Feasibility for Pathogen Detector | 1 | RNS | ||
| 11.02. | Aptamer Group PLC - Optimer Technology in Launched Library Prep Kit | - | RNS | ||
| 29.01. | Aptamer Group PLC - Contract wins and first cash licensing receipts | 1 | RNS | ||
| 07.01. | Aptamer Group PLC - Trading update - Media comment and speculation | - | RNS |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,032 | -9,04 % | PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt | DJ PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Sonstiges... ► Artikel lesen | |
| CO.DON | 0,014 | 0,00 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.04.2026.ISIN NameCA46658Y1034 J2... ► Artikel lesen | |
| TME PHARMA | 0,069 | 0,00 % | TME Pharma NV: TME Pharma publishes its annual financial results and annual report | TME Pharma publishes its annual financial results and annual report Berlin, Germany, April 30, 2026, 20.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company... ► Artikel lesen | |
| REPLENISH NUTRIENTS | 0,078 | -9,88 % | Replenish Nutrients Holding GAAP EPS of -$0.03, revenue of $2.96M | ||
| GLOW LIFETECH | 0,027 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Expands Distribution with Two of Canada's Largest Cannabis Retailers, Launches New Product Innovation and Advances National Growth Strategy | Toronto, Ontario--(Newsfile Corp. - April 30, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to provide a commercial update highlighting continued... ► Artikel lesen | |
| NEOVACS | 0,000 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.05.2026 | Das Instrument POH3 US14365C1036 CARNIVAL PLC ADR/1 DL1,66 EQUITY wird cum Kapitalmassnahme gehandelt am 06.05.2026 und ex Kapitalmassnahme am 07.05.2026 The instrument POH3 US14365C1036 CARNIVAL PLC... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,017 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| BIOVAXYS TECHNOLOGY | 0,044 | 0,00 % | CSE Bulletin: Suspensions - VSBLTY Groupe Technologies Corp., NuRAN Wireless Inc., GOAT Industries Ltd., BYT Holdings Ltd., ASEP Medical Holdings Inc., BioVaxys Technology Corp. | Le 6 mai/May 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading... ► Artikel lesen | |
| NANOSPHERE HEALTH SCIENCES | 0,008 | +400,00 % | Nanosphere Health Sciences Inc (2): Nanosphere Health adopts semi-annual reporting | ||
| TELO GENOMICS | 0,030 | +490,00 % | Telo Genomics Corp.: Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma | Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and... ► Artikel lesen | |
| ALTERITY THERAPEUTICS | 0,006 | 0,00 % | ALTERITY THERAPEUTICS LIMITED: Corporate Presentation May 2026 | ||
| MEDMIRA | 0,030 | 0,00 % | MedMira, Inc.: MedMira Reports Second Quarter Results FY2025 | HALIFAX, NS / ACCESS Newswire / April 1, 2026 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2026.Corporate updateIn Q2 FY2026, the Company... ► Artikel lesen | |
| GENETIC TECHNOLOGIES | 0,034 | -100,00 % | GENETIC TECHNOLOGIES LIMITED: Long Term Suspended Entities | ||
| BIOPHYTIS | 0,021 | +4,41 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.12.2025 | Das Instrument 6XB3 FR001400OLP5 BIOPHYTIS NAM. EO -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 09.12.2025 und ex Kapitalmassnahme am 10.12.2025 The instrument 6XB3 FR001400OLP5 BIOPHYTIS NAM.... ► Artikel lesen |